Schrödinger, Inc. (NASDAQ:SDGR) Shares Sold by AtonRa Partners

AtonRa Partners reduced its position in Schrödinger, Inc. (NASDAQ:SDGR) by 10.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 21,486 shares of the company’s stock after selling 2,636 shares during the quarter. Schrödinger makes up about 1.5% of AtonRa Partners’ investment portfolio, making the stock its 10th largest holding. AtonRa Partners’ holdings in Schrödinger were worth $769,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SDGR. SG Americas Securities LLC lifted its stake in shares of Schrödinger by 8.4% in the 4th quarter. SG Americas Securities LLC now owns 5,125 shares of the company’s stock valued at $183,000 after purchasing an additional 397 shares during the last quarter. Spire Wealth Management lifted its position in shares of Schrödinger by 66.7% in the third quarter. Spire Wealth Management now owns 1,000 shares of the company’s stock worth $28,000 after buying an additional 400 shares during the last quarter. Motley Fool Asset Management LLC boosted its stake in shares of Schrödinger by 2.0% during the 3rd quarter. Motley Fool Asset Management LLC now owns 29,402 shares of the company’s stock worth $831,000 after acquiring an additional 570 shares in the last quarter. Tudor Investment Corp Et Al boosted its stake in shares of Schrödinger by 1.0% during the 3rd quarter. Tudor Investment Corp Et Al now owns 91,725 shares of the company’s stock worth $2,593,000 after acquiring an additional 908 shares in the last quarter. Finally, Perigon Wealth Management LLC increased its holdings in shares of Schrödinger by 14.1% during the 3rd quarter. Perigon Wealth Management LLC now owns 7,811 shares of the company’s stock valued at $221,000 after acquiring an additional 964 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Schrödinger Stock Performance

Shares of NASDAQ:SDGR traded up $0.47 on Monday, hitting $24.44. 583,689 shares of the company were exchanged, compared to its average volume of 844,689. The company’s 50 day moving average price is $26.61 and its two-hundred day moving average price is $28.28. Schrödinger, Inc. has a one year low of $20.76 and a one year high of $59.24. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 38.79 and a beta of 1.57.

Schrödinger (NASDAQ:SDGR) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.12. Schrödinger had a negative return on equity of 23.58% and a net margin of 18.79%. The firm had revenue of $74.10 million for the quarter, compared to analyst estimates of $79.12 million. During the same period in the previous year, the company posted ($0.39) earnings per share. The company’s quarterly revenue was up 30.5% compared to the same quarter last year. Research analysts predict that Schrödinger, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SDGR shares. Craig Hallum reduced their target price on Schrödinger from $40.00 to $35.00 and set a “buy” rating for the company in a report on Friday, January 19th. Bank of America decreased their price objective on shares of Schrödinger from $38.00 to $32.00 and set a “neutral” rating for the company in a report on Thursday, February 29th. TD Cowen began coverage on shares of Schrödinger in a report on Friday, January 26th. They issued an “outperform” rating and a $42.00 target price on the stock. The Goldman Sachs Group cut their target price on shares of Schrödinger from $29.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, March 1st. Finally, Piper Sandler lowered their price target on Schrödinger from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Thursday, February 29th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Schrödinger presently has an average rating of “Moderate Buy” and a consensus target price of $43.50.

Insider Activity

In other Schrödinger news, insider Robert Lorne Abel sold 1,205 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $27.55, for a total value of $33,197.75. Following the sale, the insider now owns 9,340 shares of the company’s stock, valued at approximately $257,317. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Schrödinger news, insider Robert Lorne Abel sold 1,205 shares of Schrödinger stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $27.55, for a total transaction of $33,197.75. Following the sale, the insider now directly owns 9,340 shares of the company’s stock, valued at $257,317. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kenneth Patrick Lorton sold 901 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $28.29, for a total value of $25,489.29. Following the completion of the transaction, the chief operating officer now directly owns 36,487 shares of the company’s stock, valued at $1,032,217.23. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,651 shares of company stock worth $102,395. Company insiders own 7.60% of the company’s stock.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.